GlobeNewswire

Change in number of shares and votes in Better Collective A/S

Share

Regulatory Release 32/2020


During June, the number of shares and votes in Better Collective A/S has increased. As of June 30, 2020, the number of shares and votes in Better Collective A/S amounts to 46,735,673 following an issue of 12,690 new ordinary shares. 

Reference is made to Regulatory Release 28/2020 “Exercise of warrants in Better Collective A/S; Board of Directors issues 12,690 new ordinary shares” released on June 8, 2020.   


Contacts
Investor Relations: Christina Bastius Thomsen, tel. +45 2363 8844, e-mail: investor@bettercollective.com


This information is such information as Better Collective A/S is obliged to make public pursuant to the EU Market Abuse Regulation. 


About Better Collective

Better Collective’s vision is to empower iGamers through transparency and technology – this is what has made them the world’s leading developer of digital platforms for betting tips, bookmaker information and iGaming communities. Better Collective’s portfolio includes a range of websites and products, among other bettingexpert.com, the trusted home of tips from expert tipsters and in depth betting theory. Better Collective is headquartered in Copenhagen, Denmark, and listed on Nasdaq Stockholm (BETCO). 

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS18.9.2020 10:07:00 CESTPress release

Auction date2020-09-18Loan1061Coupon0.75 %ISIN-codeSE0011281922Maturity2029-11-12Tendered volume, SEK mln1,000 +/- 250Volume offered, SEK mln3,450Volume bought, SEK mln1,000Number of bids8Number of accepted bids1Average yield-0.097 %Lowest accepted yield-0.097 %Highest yield-0.097 %% accepted at lowest yield 100.00 Auction date2020-09-18Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln1,000 +/- 250Volume offered, SEK mln4,950Volume bought, SEK mln1,000Number of bids14Number of accepted bids2Average yield0.005 %Lowest accepted yield0.004 %Highest yield0.006 %% accepted at lowest yield 100.00

Saniona deltar i den virtuella konferensen Oppenheimer Fall Healthcare Life Sciences & MedTech Summit 202018.9.2020 08:00:00 CESTPressemelding

PRESSMEDDELANDE 18 september 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att företagets koncernchef och VD Rami Levin kommer att delta i ett virtuellt ”samtal vid brasan” i samband med konferensen Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit som anordnas 21-23 september 2020. Närmare uppgifter om det virtuella samtalet vid brasan presenteras nedan. Oppenheimer & Co. 2020 Fall Healthcare Life Sciences & MedTech Summit Datum: Tisdag 22 september 2020 Tid: 10.50 ET Länk till webbsändning: https://wsw.com/webcast/oppenheimer5/sanion.st/3751533 Samtalet vid brasan kommer att websändas live, och kan nås via sidan ”Intervjuer och webbsändningar” på Sanionas webbplats: https://saniona.com/se/investors/interviews-webcasts/. Efter livesändningen kommer samtalet att finnas arkiverat på Sanionas webbplats i ungefär 90 dagar. För mer information, var vänlig kontakta Trista Morrison, Chief Communi

Saniona to Participate in Oppenheimer’s Virtual 2020 Fall Healthcare Life Sciences & MedTech Summit18.9.2020 08:00:00 CESTPress release

PRESS RELEASE September 18, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that Rami Levin, President and Chief Executive Officer of Saniona, will participate in a virtual fire side chat at the Oppenheimer & Co. Fall Healthcare Life Sciences & MedTech Summit being held September 21–23, 2020. Details on the virtual fire side chat are shown below. Oppenheimer & Co. 2020 Fall Healthcare Life Sciences & MedTech Summit Date: Tuesday September 22, 2020 Time: 10:50 a.m. ET Webcast Link: https://wsw.com/webcast/oppenheimer5/sanion.st/3751533 A live webcast of the fire side chat will be available in the Interviews & Webcasts section of the Saniona website found here: https://saniona.com/investors/interviews-webcasts/. After the live webcast, this event will remain archived on the Saniona website for approximately 90 days. For more information, please contact Trista Morrison, Chief Communications Officer. Mobile + 1 (781) 810 9227

Scandinavian Tobacco Group A/S issues EUR 300 million Corporate Bond18.9.2020 08:00:00 CESTPress release

Company Announcement No. 27/2020 Copenhagen, 18 September 2020 Scandinavian Tobacco Group A/S issues EUR 300 million Corporate Bond The information contained herein is not a release, publication or distribution, directly or indirectly, in or into the United States, Canada, Japan or Australia or any other jurisdiction in which such release, publication or distribution would be unlawful.This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities in Scandinavian Tobacco Group A/S or STG Global Finance B.V. in the United States, Canada, Japan or Australia or any other jurisdiction. STG Global Finance B.V., a wholly-owned subsidiary of Scandinavian Tobacco Group A/S, has successfully priced an issuance of a 5 year unsecured corporate bond for a principal amount of EUR 300 million with maturity in September 2025 and with a coupon of 1.375%. The issuance was more than two times oversubscribed. The bonds are guaranteed by Scandinavian Tobacco Group

Scandinavian Tobacco Group A/S udsteder EUR 300 millioner erhvervsobligationer18.9.2020 08:00:00 CESTpressemeddelelse

Selskabsmeddelelse Nr. 27/2020 København, 18. september 2020 Scandinavian Tobacco Group A/S udsteder EUR 300 millioner erhvervsobligationer Denne meddelelse og indholdet heraf må ikke udleveres, offentliggøres eller distribueres, direkte eller indirekte, i USA, Canada, Japan eller Australien eller i nogen anden jurisdiktion, hvor udlevering, offentliggørelse eller distribution ville være ulovlig.Denne meddelelse udgør ikke et tilbud om at sælge eller en opfordring til at fremsætte tilbud om at købe nogen værdipapirer i Scandinavian Tobacco Group A/S eller STG Global Finance B.V. i USA, Canada, Japan eller Australien eller nogen anden jurisdiktion. STG Global Finance B.V., et helejet datterselskab til Scandinavian Tobacco Group A/S, har gennemført prisning af en udstedelse af en 5-års usikret erhvervsobligation garanteret af Scandinavian Tobacco Group A/S med en hovedstol på EUR 300 millioner, forfald i september 2025 og en kuponrente på 1,375 %. Udstedelsen blev overtegnet lidt over to

Roche launches new quantitative antibody test to measure SARS-CoV-2 antibodies, to support the evaluation of vaccines18.9.2020 07:03:00 CESTPress release

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. This is the focus of vaccines in development and convalescent plasma therapy.1Using the Elecsys Anti-SARS-COV-2 S antibody test, together with the Elecsys Anti-SARS-CoV-2* test launched in May, can help to more effectively determine the percentage of a population who already have antibodies against SARS-COV-2. Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark. Roche has filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA). The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can p